Clinical Trial

TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC

Study acronym: TACE HCC
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, multicenter, prospective clinical trial designed to evaluate the efficacy and safety of Transarterial Chemoembolization (TACE) combined with envafolimab in patients with unresectable, non-metastatic hepatocellular carcinoma (HCC), while exploring potential biomarkers associated with treatment response.
Trial Details
NCT Number NCT06990620
Lead Sponsor Fudan University
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 56 participants
Start Date 2025-06
Primary Completion 2027-06 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-05-25